ARROTEX Pharmaceuticals and Bayer Australia have announced a strategic partnership under which Arrotex will assume sales, marketing and distribution responsibilities for Bayer's established portfolio of oral contraceptive brands in Australia.
The agreement brings together Bayer's heritage and expertise in women's healthcare with Arrotex's extensive reach across Australia's retail pharmacy network, enabling broader, more consistent access to Bayer's products, Yaz (drospirenone/ethinylestradiol) and Yasmin (drospirenone/ethinylestradiol).
Both products were listed on the PBS from 01 Mar (PD 10 Feb), and the new partnership reflects a commitment on both sides to protecting and increasing access to the oral contraceptives.
"We are proud to partner with Bayer to expand the availability and visibility of its established oral contraceptive portfolio in Australia," explained Arrotex's Chief Commercial Officer, Hayley Tamborini.
"Our mission is to ensure that the PBS listing translates to real-world access."
Matthew Donnison, GM of Strategic Partnerships at Arrotex, observed that the partnership means the brands can benefit from Arrotex's commercial expertise and ability to engage with pharmacists across the country, ensuring more Australian women can access the medicines reliably, locally and affordably.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 25
